Clinicopathological profile of bilateral breast cancer at a tertiary cancer center in South India

Abstract

Background Bilateral breast cancer (BBC) is an unusual clinical entity. Unlike unilateral breast cancer, there is fewer data regarding clinicopathological aspects and treatment guidelines in BBC. The present study was carried out at a tertiary oncology center in South India to analyze the clinicopathological profile of patients diagnosed with BBC.Methods This was a retrospective observational study of patients diagnosed with BBC in the department of medical oncology from August 2012 to July 2013.Results Out of a total of 300 breast cancer patients during a 1-year period, 15 had BBC. Synchronous and metachronous breast cancers were seen in six and nine patients, respectively. The median age at presentation for BBC was 40 years. Family history of breast cancer was present only in two cases. The median age of menarche and first child birth was 13 and 22 years, respectively. History of breast feeding was positive in all except one who was nulliparous. Out of the 15 patients, 11 were premenopausal and 4 postmenopausal. Contralateral breast cancer was detected mammographically in 4 patients and by clinical examination in 11. Out of 30 tumors, all were invasive ductal carcinomas (IDC). Nine patients had bilateral mastectomy, and five had unilateral mastectomy. Out of 30 tumors, 14 were triple negative, 9 estrogen receptor (ER)/progesterone (PR) positive, and 7 Her2neu positive. Neoadjuvant chemotherapy (NACT) was given in four synchronous and three metachronous breast cancer cases for contralateral breast cancer. All patients received chemotherapy during the course in the form of either adjuvant or palliative chemotherapy.Conclusions BBC is an uncommon clinical entity. For women with younger premenopausal age, the incidence of BBC is higher compared with older women. As the prognosis of BBC is poor, it is crucial to be aware of this entity, and every patient with breast cancer should be regularly followed up. These patients require individualized treatment planning based on the tumor factors and treatment factors of the primary lesion.

RETRACTED: miR‐655 suppresses epithelial‐to‐mesenchymal transition by targeting Prrx1 in triple‐negative breast cancer

“…Triple-negative breast cancer (TNBC) is a highly aggressive tumour subtype associated with a poor prognosis, and most mortality and morbidity does not arise from the primary tumour, but from distant metastasis [1,2]. To metastasize, a cancer cell must shed many of its epithelial characteristics, invade the surrounding tissue to enter the circulation, subsequently survive in the circulation, extravasate and proliferate in the metastatic niche [3,4].…”

Bilateral breast cancer in a Nigerian community

“…The proportion was 83.3% locally. As regards the median age, Indian authors obtained 40 years, while a Korean group got 41 years, and a Chinese case was 43 years old [9][10][11]. The present cohort came to the close 42.5 years.…”

Unrevealing the role of miRNA in successful TNBC treatment: A pilot study to explore the chemotherapy drugs for timely treatment of TNBC

“…Family history plays a big role in predicting the likelihood of having TNBC. 30 Only 7 (28%) of the TNBC patients in our study provided a positive family history, while 18 (72%) of the patients provided a negative one. This is in contrast to other research' findings, which indicated a high association between a family history of breast cancer and its progression, particularly TNBC.…”